Literature DB >> 15964451

Recognition and management of complications of new recreational drug use.

George A Ricaurte1, Una D McCann.   

Abstract

Use of illicit drugs in clubs and large dance parties (so-called raves) is a burgeoning cultural trend. Such recreational drug use is associated with several medical complications, both acute and longlasting. Although few, if any, of the drugs currently used in recreational venues are truly new, their patterns and context of use have changed (a great deal in some instances). For some of these substances, this cultural repackaging of the drug experience has resulted in various medical disorders that have previously gone undocumented. This review aims to help treating physicians recognise and manage complications associated with the use of new drugs in clubs, including methylenedioxymethamfetamine, ephedrine, gamma-hydroxybutyrate; gamma-butyrolactone, 1,4-butanediol, flunitrazepam, ketamine, and nitrites. We also alert researchers to specific toxic effects of club-drugs on which more basic information is needed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964451     DOI: 10.1016/S0140-6736(05)66737-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

Review 1.  [Party and designer drugs : From ecstasy and crystal meth to angel's trumpet].

Authors:  F Erbguth
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-10-19       Impact factor: 0.840

Review 2.  [Ephedrine as alternative to Akrinor in regional obstetric anesthesia].

Authors:  L Aniset; C Konrad; M Schley
Journal:  Anaesthesist       Date:  2006-07       Impact factor: 1.041

3.  Gamma-hydroxybutyric acid in male and female cynomolgus monkeys trained to discriminate 1.0 or 2.0 g/kg ethanol.

Authors:  Christa M Helms; Laura S M Rogers; Kathleen A Grant
Journal:  Behav Pharmacol       Date:  2008-07       Impact factor: 2.293

4.  Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY.

Authors:  David M Wood; Jemma J Looker; Loua Shaikh; Jenny Button; Malgorzata Puchnarewicz; Susannah Davies; Satnam Lidder; John Ramsey; David W Holt; Paul I Dargan
Journal:  J Med Toxicol       Date:  2009-12

Review 5.  Ecstasy-associated pneumomediastinum.

Authors:  Silvana F Marasco; H Kiat Lim
Journal:  Ann R Coll Surg Engl       Date:  2007-05       Impact factor: 1.891

6.  Harm reduction strategies related to dosing and their relation to harms among festival attendees who use multiple drugs.

Authors:  Fermín Fernández-Calderón; Carmen Díaz-Batanero; Monica J Barratt; Joseph J Palamar
Journal:  Drug Alcohol Rev       Date:  2018-10-09

7.  Effects of MDMA on blood glucose levels and brain glucose metabolism.

Authors:  M L Soto-Montenegro; J J Vaquero; C Arango; G Ricaurte; P García-Barreno; M Desco
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-12       Impact factor: 10.057

8.  Gene expression changes in GABA(A) receptors and cognition following chronic ketamine administration in mice.

Authors:  Sijie Tan; John A Rudd; David T Yew
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

9.  The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup.

Authors:  Michael P Wilson; David Pepper; Glenn W Currier; Garland H Holloman; David Feifel
Journal:  West J Emerg Med       Date:  2012-02

Review 10.  Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review.

Authors:  Fabio Caputo; Teo Vignoli; Icro Maremmani; Mauro Bernardi; Giorgio Zoli
Journal:  Int J Environ Res Public Health       Date:  2009-06-24       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.